Skip to main content

Table 4 HSUVs associated with CRC treatments and AEs

From: Systematic review of health state utility values for economic evaluation of colorectal cancer

Reference

Valuation methods used

HSUVs

Bennett [56]

EQ-5D

1st line

Panitimumab + FOLFOX4 0.778; FOLFOX4 0.756

2nd line

Panitimumab + FOLFIRI 0.769; FOLFIRI 0.762

Best [4]

TTO

CRC patients/community members

Remission 0.83/0.82

adjuvant, no neuropathy 0.61/0.60

adjuvant, mild neuropathy 0.61/0.51

adjuvant, moderate neuropathy 0.53/0.46

adjuvant, severe neuropathy 0.48/0.34

metastatic, stable 0.40)/0.51

metastatic, progressive 0.37/0.21

Dranitsaris [48]b

TTO

FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–33 months] 0.68-0.89

FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.70-0.94

Dranitsaris [36]b

TTO

FOLFOX±’new drug’ → FOLFIRI → BSC until death [2–29 months] 0.67-0.83

FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.72-0.91

Dranitsaris [48]b

TTO

FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–29 months] 0.52-0.84

FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.53-0.84

Dranitsaris [36]b

TTO

FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–28 months] 0.44-0.72

FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.44-0.71

Farkkila [51]

EQ-5D

Metastatic disease 0.820

Palliative care 0.643

Mittmann [38]b

HUI3

Cetuximab + BSC 0.71-0.77

BSC 0.66-0.71

Odom [58]

EQ-5D

Panitumumab plus BSC; BSC alone

Overall 0.72; 0.68

Wild-type KRAS 0.73; 0.68

Mutant KRAS 0.71; 0.68

Petrou [20]a

SG

Partial response 1.0

Stable disease 0.95

Progressive disease 0.575

Terminal disease 0.1

Shiroiwa [44]

TTO

XELOX without AEs 0.59

FOLFOX without AEs 0.53

Febrile neutropenia 0.39

Nausea/vomiting 0.38

Diarrhoea 0.42

Hand-foot syndrome 0.39

Fatigue 0.45

Peripheral neuropathy 0.45

Stomatitis 0.42

Wang [60]

EQ-5D

Panitumumab + BSC; BSC

TOX 0.6008; 0.4409

TWiST 0.7678; 0.6630

REL 0.6318; 0.6407

Wiering [29]

EQ-5D

Disease-free 0.78

non-curative 0.67

recurrence 0.74

recurrence with chemotherapy 0.82

Recurrent without chemotherapy 0.68

Ward [14]

EQ-VAS

Capecitabine and bevacizumab

Baseline 61.76 (SD 23.15)

Cycle 2 68.59 (SD 22.26) [p = 0.06]

End of study 66.54 (SD 23.18) [p = 0.29]

  1. aReported HSUVs are re-expressed on a 0–1 scale
  2. bRanges of reported HSUVs
  3. AE adverse event, BSC best supportive care, FOLFOX Oxaliplatin + infusional 5 fluorouracil (5-FU), FOLFIRI Irinotecan + infusional 5 fluorouracil (5-FU), FOLFOX4 5-fluorouracil/folic acid and oxaliplatin, HSUVs health state utility values, KRAS Kirsten rat sarcoma viral oncogene, REL (relapse period until death or end of follow-up), SD standard deviation, SG Standard gamble, TOX days with ≥ grade 3 adverse events, TTO time trade-off, TWiST time without symptoms or toxicity, XELOX capecitabine plus oxaliplatin